Why is Zealand Pharma stock sliding today? By Investing.com
Jefferies downgraded Zealand Pharma (ZELA) from Buy to Hold and cut its price target to DKK 320 from DKK 505, citing no near-term value catalysts in 2H 2026. It reduced the probability of success for survodutide to 40% from 60% due to tolerability concerns after Phase III data. Shares fell about 2% with no Zealand-specific news.
How this was made
The 30-second read
Why it matters
A same-day sell-side downgrade with a materially lower price target and reduced success probability for survodutide is presented as the dominant driver of ZELA’s decline, while meaningful inflection is framed as unlikely before 2027.
Market read
Traders can treat this as a catalyst-driven sentiment reset for ZELA tied to survodutide tolerability and delayed inflection timing.
What to watch
The article highlights tolerability concerns for survodutide but does not quantify how much of the market reaction is already priced versus what additional data could change the risk profile into 2027.
Background
Zealand Pharma’s lead pipeline includes survodutide (glucagon/GLP-1 dual agonist) and petrelintide (amylin analog), with survodutide’s Phase III tolerability profile under scrutiny.
Market effects
Reinforces broader sell-side caution on GLP-1/glucagon and tolerability-driven read-throughs for next-gen incretin franchises.
Copenhagen OMXC25 weakness suggests Denmark biotech risk appetite is pressured alongside global equities.
US risk-off backdrop can amplify de-rating of clinical-stage biotech names when catalysts are pushed out.
Counterpoint
The downgrade may be largely expectations-resetting; investors could look past near-term timing if petrelintide Phase 3 progress with Roche provides a new catalyst.
Key entities
- companyZealand Pharma
Danish biotech whose shares fell after Jefferies downgraded the stock and cut its survodutide assumptions.
- analyst_firmJefferies
Downgraded ZELA from Buy to Hold and cut price target to DKK 320 from DKK 505.
- partnerBoehringer Ingelheim
Partner on survodutide, referenced in the lowered probability of success.
- partnerRoche
Collaborator advancing petrelintide into Phase 3 trials.
